Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment.
Research output: Contribution to journal › Article
Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastasis. A target molecule of tasquinimod is the inflammatory protein S100A9 which has been shown to affect the accumulation and function of suppressive myeloid cell subsets in tumors. Given the major impact of myeloid cells to the tumor microenvironment, manipulation of this cell compartment is a desirable goal in cancer therapeutics.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal for ImmunoTherapy of Cancer|
|Publication status||Published - 2015|